LONDON--(BUSINESS WIRE)--CHARM Therapeutics, a 3D deep learning biotechnology company discovering and developing transformational medicines, today announced the promotion of Sarah Skerratt, Ph.D., to Chief Scientific Officer (CSO), and the appointment of Laura Hare as Chief People Officer and Head of Business Operations..

伦敦--（商业新闻短讯）--CHARM Therapeutics是一家发现和开发转化药物的3D深度学习生物技术公司，今天宣布将Sarah Skerratt博士提升为首席科学官（CSO），并任命Laura Hare为首席人事官和业务运营主管。。

“These leadership updates mark a transformative phase for CHARM. Sarah’s promotion to CSO is a testament to her exceptional contribution to our pipeline, and we’re excited to welcome Laura, whose experience will be pivotal in our next growth phase,” said Laksh Aithani, co-founder and CEO of CHARM Therapeutics..

CHARM Therapeutics联合创始人兼首席执行官拉克什·艾塔尼（LakshAithani）表示：“这些领导层的更新标志着CHARM进入了一个变革阶段。Sarah晋升为CSO证明了她对我们的渠道做出了非凡的贡献，我们很高兴欢迎Laura，她的经验将对我们的下一个成长阶段至关重要。”。。

Dr. Sarah Skerratt’s promotion to CSO comes as CHARM’s pipeline achieves significant progress under her leadership and expertise. Bringing over 20 years of experience in drug discovery, Skerratt is a leader with a strong record of delivery from the exploratory phase to the clinic across several therapeutic areas.

SarahSkerratt博士晋升为CSO之际，CHARM的管道在她的领导和专业知识下取得了重大进展。Skerratt在药物发现方面拥有20多年的经验，是一位在多个治疗领域从探索阶段到临床的强大记录的领导者。

Her extensive tenure includes senior positions at Merck Sharp & Dohme, Vertex, Convergence/Biogen and Pfizer Inc., solidifying her reputation in drug discovery and development. She is an organic chemist by training, holding a Ph.D. from the University of Nottingham and having completed postdoctoral studies at Stanford University as a visiting Fulbright Scholar..

她在默克制药、Vertex、Convergence/Biogen和辉瑞公司担任高级职位，巩固了她在药物发现和开发方面的声誉。她是一名受过训练的有机化学家，拥有诺丁汉大学的博士学位，并以访问富布赖特学者的身份在斯坦福大学完成了博士后研究。。

Laura Hare joins CHARM from F-star Therapeutics, where she was instrumental as Senior Vice President of Corporate Operations and People and led the organisation through multiple transformations from early drug discovery to its successful acquisition by invoX Pharma. With 20 years of experience in scale-up and high-growth companies across both tech and biotech, her experience will be critical in leading CHARM’s rapid growth and nurturing a thriving workplace culture.

劳拉·黑尔（LauraHare）加入了F-star Therapeutics的CHARM，她在F-star Therapeutics担任公司运营和人员高级副总裁，并带领该组织经历了从早期药物发现到被invoX Pharma成功收购的多次转型。凭借20年在科技和生物技术领域的规模化和高增长公司的经验，她的经验对于领导CHARM的快速增长和培育繁荣的工作场所文化至关重要。

Hare’s expertise in corporate operations and human resources is expected to play a significant role in CHARM’s strategy and operational management as the company continues to expand..

随着公司的不断扩张，Hare在企业运营和人力资源方面的专业知识有望在CHARM的战略和运营管理中发挥重要作用。。

About CHARM Therapeutics

关于魅力疗法

CHARM Therapeutics is discovering and developing small molecule medicines against difficult-to-drug targets with its proprietary 3D deep learning-enabled platform, DragonFold. Powered by the first high throughput protein-ligand co-folding algorithm and a world-class team of scientists and engineers, CHARM seeks to deliver innovative approaches to create life-changing therapies for patients..

CHARM Therapeutics凭借其专有的3D深度学习平台DragonFold，正在发现和开发针对难以药物靶点的小分子药物。在第一个高通量蛋白质-配体共折叠算法和世界一流的科学家和工程师团队的支持下，CHARM寻求提供创新方法，为患者创造改变生命的疗法。。

Cambridge and London-based CHARM has raised $70 million to date and is building an interdisciplinary and entrepreneurial team, combining leaders from the fields of AI and biotechnology. It is supported by high quality international investors including OrbiMed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA and grep -vc.

剑桥和伦敦的CHARM迄今已筹集了7000万美元，并正在建立一个跨学科和创业团队，由人工智能和生物技术领域的领导者组成。它得到了高质量国际投资者的支持，包括OrbiMed、F-Prime Capital、General Catalyst、Khosla Ventures、Bristol-Myers Squibb、NVIDIA和grep-vc。

For more information, please visit: www.charmtx.com.

有关更多信息，请访问：www.charmtx.com。